مركب تعزيز انتشار الأكسجين (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "مركب تعزيز انتشار الأكسجين" in Arabic language version.

refsWebsite

Global rank Arabic rank

8doi.org

2^nd place

5^th place

8nih.gov

4^th place

6^th place

3espacenet.com

800^th place

1,795^th place

2web.archive.org

1^st place

2archive.org

6^th place

3^rd place

1clinicaltrials.gov

5,225^th place

3,308^th place

1diffusionpharma.com

low place

archive.org

Cannon، Joseph G (1999). Pharmacology for Chemists. New York: Oxford University Press. ISBN:978-0841235243.
Starr، Cecie؛ McMillan، Beverly (2012). Human Biology (ط. 9th). ISBN:978-0840061669.

clinicaltrials.gov

"Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". موقع التجارب السريرية. نوفمبر 2011. مؤرشف من الأصل في 2020-08-20. اطلع عليه بتاريخ 2012-09-18.

diffusionpharma.com

investors.diffusionpharma.com

"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. 5 مايو 2020. مؤرشف من الأصل في 2020-08-17. اطلع عليه بتاريخ 2020-05-25.

doi.org

Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Gainer J؛ G.M. Chisolm III (1974). "Oxygen diffusion and atherosclerosis". Atherosclerosis. ج. 19 ع. 1: 135–138. DOI:10.1016/0021-9150(74)90049-5. PMID:4810465.
"Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials". Cancer Detection and Prevention. ج. 28 ع. 6: 426–432. 2004. DOI:10.1016/j.cdp.2004.09.002. PMID:15582266.
Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Lapchak P (2010). "Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator". Brain Research. ج. 1309: 136–145. DOI:10.1016/j.brainres.2009.10.067. PMID:19891959.
Sheehan, Jason؛ وآخرون (2008). "Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation". Journal of Neurosurgery. ج. 108 ع. 5: 972–978. DOI:10.3171/JNS/2008/108/5/0972. PMID:18447715.
Laidig, K.E., J.L. Gainer, V. Daggett (1998). "Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics". Journal of the American Chemical Society. ج. 120 ع. 36: 9394–9395. DOI:10.1021/ja981656j.{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

espacenet.com

worldwide.espacenet.com

US patent 8206751, Gainer J, "New Class of Therapeutics that Enhance Small Molecule Diffusion", issued 2009-04-30
[1]
[2]

nih.gov

pubmed.ncbi.nlm.nih.gov

Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Gainer J؛ G.M. Chisolm III (1974). "Oxygen diffusion and atherosclerosis". Atherosclerosis. ج. 19 ع. 1: 135–138. DOI:10.1016/0021-9150(74)90049-5. PMID:4810465.
"Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials". Cancer Detection and Prevention. ج. 28 ع. 6: 426–432. 2004. DOI:10.1016/j.cdp.2004.09.002. PMID:15582266.
Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Lapchak P (2010). "Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator". Brain Research. ج. 1309: 136–145. DOI:10.1016/j.brainres.2009.10.067. PMID:19891959.
Sheehan, Jason؛ وآخرون (2008). "Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation". Journal of Neurosurgery. ج. 108 ع. 5: 972–978. DOI:10.3171/JNS/2008/108/5/0972. PMID:18447715.
"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

ncbi.nlm.nih.gov

"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

web.archive.org

"Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". موقع التجارب السريرية. نوفمبر 2011. مؤرشف من الأصل في 2020-08-20. اطلع عليه بتاريخ 2012-09-18.
"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. 5 مايو 2020. مؤرشف من الأصل في 2020-08-17. اطلع عليه بتاريخ 2020-05-25.